This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Israel Makov Appointed Chairman Of Sun Pharma Board

MUMBAI, May 29, 2012 /PRNewswire/ --

The Board of Directors of Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) met today and announced appointment of Mr Israel Makov as Chairman of the Board.

Mr. Makov is the former President and CEO of Teva Pharmaceutical Industries Ltd (2002-2007). He is among Israel's most respected corporate leaders, and is widely credited with Teva's emergence as a global company and a world leader in generic pharmaceuticals.

Speaking on the induction, Mr Dilip Shanghvi, Managing Director of Sun Pharma said "I welcome Mr Makov on behalf of the entire Board and the larger Sun Pharma team.  He is an exceptional leader with deep knowledge and experience in globalizing businesses successfully.  As Sun Pharma continues to rapidly expand its presence worldwide, I am sure that we will benefit immensely from his experience."

On his appointment, Mr Makov said, "I am happy to accept the position of Chairman of the Board.  Sun Pharma is an exciting company poised for substantial global expansion and I look forward to working together with Dilip and his team in realizing their visionary goals."

Profile of Mr Israel Makov

Mr Makov is the former President and CEO of Teva Pharmaceutical Industries Ltd.  He joined Teva in 1995 and led the company's global expansion, managing over 12 acquisitions - two of which were the largest M&A deals in the Israeli history at the time.  Under Mr Makov's leadership, Teva became the undisputed global leader in generic pharmaceutical industry and a global leader in the treatment of Multiple sclerosis.  Prior to joining Teva in 1995, Mr. Makov led a number of companies in various industries, and founded Israel's first biotech company, Interpharm which went public in the US as the first Israeli company in R&D stage.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,776.91 +93.33 0.53%
S&P 500 2,081.34 +12.58 0.61%
NASDAQ 4,997.4590 +5.5190 0.11%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs